Fact CheckerSign in

NCT02829606Completed

Head Mounted Eye Tracking Aide for Loss of Central Vision (HETALCEV)

Head Mounted Eye Tracking Aide for Loss of Central Vision

Source: ClinicalTrials.gov · Last updated 20 Jun 2024

Brief summary (registry, in English)

A device has been developed that has eye trackers integrated within the Head Mounted Display (HMD) and can remap text and images around the scotoma in real time to prevent information loss from a central scotoma. It can also carry out other types of image processing such as contrast enhancement and image magnification. The aim of this study is to assess the efficacy of this device on the visual performance of participants suffering from central vision loss, with and without remapping

Status (registry)
Completed
Study type
Interventional
Enrollment
8 (actual)
First submitted
13 Jun 2016
Start date
Apr 2016
Primary completion date
Apr 2023
Lead sponsor
University of Minnesota
NCT number
NCT02829606

What you commit to

  • Study type: Interventional
  • Participants enrolled: 8
  • From Apr 2016 to the primary completion date, Apr 2023
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Failed MMSE

Who the study is looking for

  • 18 years or older
  • Central vision loss from bilateral central scotomas
  • No cognitive impairment as indicated by a Mini-Mental State Examination (MMSE)

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Minnesota
Coordinator of this site? Confirm its status
MinneapolisUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.